🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
SOPHiA GENETICS SA (SOPH)
NASDAQ: SOPH Β· Real-Time Price Β· USD
6.23
-0.45 (-6.74%)
At close: Nov 20, 2026, 4:00 PM EST
6.22
-0.01 (-0.16%)
After-hours: Nov 20, 2026, 7:39 PM EST

SOPHiA GENETICS Earnings Call Transcripts

Fiscal Year 2026

  • The global network and scalable platform underpin clinical adoption and biopharma opportunities in CDx, real-world evidence, and AI predictors. U.S. growth exceeded 50% YoY; management targets adjusted EBITDA profitability in Q4 next year and sees biopharma potentially reaching half of revenue over time.

  • Q3 revenue rose 25% YoY, with record platform volume and strong U.S., liquid biopsy, and biopharma momentum; adjusted EBITDA loss improved 31%. FY26 revenue is now expected at the upper end of guidance, while FX and implementation timing remain factors.

  • Q2 2026 saw 27% revenue growth and strong U.S. performance, with new CDx deals and a JV with MSK fueling future growth. Guidance was raised to $94M-$96M, and adjusted EBITDA loss improved 27% year-over-year. Cash reserves now stand at $107.7M.

  • The company leverages a global, cloud-based AI platform for precision medicine, supporting rapid growth in genomic analysis and strong customer retention. Strategic partnerships, expanding applications, and a decentralized model drive revenue growth and position the firm for profitability by 2027.

  • Q1 2026 saw 22% revenue growth, record platform usage, and strong global expansion, with adjusted gross margin at 75.4% and net dollar retention up to 117%. Guidance for 2026 is reaffirmed, with growth expected to accelerate in the second half as new customers come online.

  • Leadership transition will bring a new CEO focused on commercial growth, with the founder moving to executive chairman. The company targets accelerated revenue growth through 2026, driven by U.S. market momentum, AI-powered platform differentiation, and expanding partnerships with leading academic centers.

Fiscal Year 2025

Fiscal Year 2024

Fiscal Year 2023

Fiscal Year 2022